tiprankstipranks
Trending News
More News >
Advertisement
Advertisement

Novavax raises FY25 adjusted revenue view to $1.04B-$1.06B from $1B-$1.05B

FY25 consensus $1.05B. Backs FY25 Nuvaxovid product sales view $610M.

Meet Your ETF AI Analyst

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & DisclosureReport an Issue

1